27 related articles for article (PubMed ID: 32452467)
1. Understanding multi-kinase inhibitor-associated cutaneous ulcers may provide molecular insights into the aetiology of pyoderma gangrenosum: A comment on Jeon et al.
Pham JP; Flora A; Frew JW
Australas J Dermatol; 2024 May; 65(3):e81-e84. PubMed ID: 38337172
[No Abstract] [Full Text] [Related]
2. Granulomatous pyoderma gangrenosum in a patient with ulcerative colitis.
Irie K; Yamamoto M; Kikuchi N; Yamamoto T
Dermatol Online J; 2020 May; 26(5):. PubMed ID: 32621701
[TBL] [Abstract][Full Text] [Related]
3. Skin ulcers misdiagnosed as pyoderma gangrenosum.
Weenig RH; Davis MD; Dahl PR; Su WP
N Engl J Med; 2002 Oct; 347(18):1412-8. PubMed ID: 12409543
[TBL] [Abstract][Full Text] [Related]
4. Pyoderma Gangrenosum Associated with Sunitinib: A Case Report.
Sevimli Dikicier B
Adv Skin Wound Care; 2019 Sep; 32(9):427-429. PubMed ID: 31408027
[TBL] [Abstract][Full Text] [Related]
5. [Sunitinib-induced pyoderma gangrenosum].
Schmutz JL; Trechot P
Ann Dermatol Venereol; 2013 Dec; 140(12):841-2. PubMed ID: 24315238
[No Abstract] [Full Text] [Related]
6. A case of pyoderma gangrenosum possibly associated with sunitinib treatment.
Ueharaguchi Y; Kabashima K; Sasahashi M; Matsuda A; Matubara K; Matsui M
Int J Dermatol; 2013 May; 52(5):634-6. PubMed ID: 23590380
[No Abstract] [Full Text] [Related]
7. Pyoderma gangrenosum with the use of sunitinib.
Nadauld LD; Miller MB; Srinivas S
J Clin Oncol; 2011 Apr; 29(10):e266-7. PubMed ID: 21220606
[No Abstract] [Full Text] [Related]
8. Sunitinib induced pyoderma gangrenosum-like ulcerations.
Akanay-Diesel S; Hoff NP; Kürle S; Haes J; Erhardt A; Häussinger D; Schulte KW; Bölke E; Matuschek C; Budach W; Gerber PA; Homey B
Eur J Med Res; 2011 Nov; 16(11):491-4. PubMed ID: 22027642
[TBL] [Abstract][Full Text] [Related]
9. Pyoderma gangrenosum-like ulceration of the lower extremity secondary to sunitinib therapy: a case report.
Lopez Pineiro M; Willis E; Yao C; Chon SY
SAGE Open Med Case Rep; 2018; 6():2050313X18783048. PubMed ID: 29977559
[TBL] [Abstract][Full Text] [Related]
10. Paradoxical Reactions: Anti-Tumor Necrosis Factor Alpha Agents, Ustekinumab, Secukinumab, Ixekizumab, and Others.
Puig L
Curr Probl Dermatol; 2018; 53():49-63. PubMed ID: 29131037
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
[TBL] [Abstract][Full Text] [Related]
12. Sunitinib-induced pyoderma gangrenosum-like skin ulcer.
Kuntz T; Koushk-Jalali B; Kreuter A
CMAJ; 2020 May; 192(20):E552. PubMed ID: 32452467
[No Abstract] [Full Text] [Related]
13. Drug-Induced Pyoderma Gangrenosum: A Review.
Wang JY; French LE; Shear NH; Amiri A; Alavi A
Am J Clin Dermatol; 2018 Feb; 19(1):67-77. PubMed ID: 28624960
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
